Traders watch earnings announcements keenly, as changes in a company’s financials can be a good indication whether a company is on the right track, or headed the wrong way.

Altus Pharmaceuticals Inc. (ALTU) is scheduled to release its earnings results Monday. The company currently has an earnings per share ratio (EPS trailing twelve months) of -2.33 and investors are hoping to see that number change. Let’s take a look at the performance of the stock since its previous earnings release.

{loadposition link_newslink1}

In the past three months, the stock has posted a -83.87% loss in terms of stock price. Over the same period, the Biotechnology industry group has returned a combined -1.07% loss.

So the eyes of investors turn to this new round of earnings.

Now, good earnings don’t always lead to higher stock prices, but keeping up on earnings is still a vital part of your fundamental stock analysis. Also note that companies often change earnings dates, so you should double-check them often.

When looking at earnings, it’s very helpful to see how stocks compare to others in its industry group. And even though two stocks may not be direct competitors, many analysts and institutional investors still compare them and evaluate them relative to other stocks in their group.  

ALTU is in the Biotechnology industry group where it competes for investor dollars with companies like La Jolla Pharmaceutical Co. (LJPC), which released its earnings on 10/30 and last reported a 89.96% gain in quarter-over-quarter EPS.

Another industry peer, Senesco Technologies Inc. (SNT) released its earnings on 09/29 and last reported a 12.29% gain in QOQ EPS.

Amgen Inc. (AMGN) is the stock with the biggest market cap in the Biotechnology industry at $56.82B. It closed yesterday at $56.14

To better understand how to evaluate earnings announcements and the affect they have on your portfolio, be sure to read Earnings Announcements and EPS.

{loadposition link_nowtime}

{loadposition followus} 

Investors watch earnings releases keenly, as changes in a company’s performance can be a good indication whether a company is on the right track, or headed the wrong way.

Transcept Pharmaceuticals, Inc. (TSPT) is scheduled to release its earnings results Thursday. The company currently has an earnings per share ratio (EPS trailing twelve months) of -3.18 and investors are hoping to see that number change. Let’s take a look at the performance of the stock since its previous earnings release.

{loadposition link_newslink1}

In the past three months, the stock has posted a -45.36% loss in terms of stock price. Over the same period, the Biotechnology industry group has returned a combined - .65% loss.

So the eyes of investors turn to this new round of earnings.

Now, good earnings don’t always lead to higher stock prices, but keeping up on earnings is still a vital part of your fundamental stock analysis. Also note that companies often change earnings dates, so you should double-check them often.

When looking at earnings, it’s very helpful to see how stocks compare to others in its industry group. And even though two stocks may not be direct competitors, many analysts and institutional investors still compare them and evaluate them relative to other stocks in their group.  

TSPT is in the Biotechnology industry group where it competes for investor dollars with companies like Cerus Corporation (CERS), which released its earnings on 10/29 and last reported a 32.66% gain in quarter-over-quarter EPS.

Another industry peer, ZIOPHARM Oncology, Inc. (ZIOP) released its earnings on 10/27 and last reported a 63.23% gain in QOQ EPS.

Amgen Inc. (AMGN) is the stock with the biggest market cap in the Biotechnology industry at $55.66B. It closed yesterday at $54.78

To better understand how to evaluate earnings announcements and the affect they have on your portfolio, be sure to read Earnings Announcements and EPS.

{loadposition link_nowtime}

{loadposition followus}